University of Brescia   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Brescia Italy (1982)

Organization Overview

First Clinical Trial
1994
NCT00002555
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Alfredo Berruti | A.O. Ospedale Papa Giovanni XXIII | A.O. Papa Giovanni XXIII | A.O. Papa Giovanni XXIII di Bergamo, Oncologia Medica | A.O. Papa Giovanni XXIII di Bergamo USC Ematologia | A.O.U. San Giovanni Battista Molinette | ASST - Papa Giovanni XXIII | ASST Papa Giovanni XXIII | ASST Papa Giovanni XXIII, Bergamo, Italy | ASST Papa Giovanni XXIII, Bergamo, Italy/IRCCS - Mario Negri Institute for Pharmacological Research | ASST Spedali Civili, Brescia | ASST Spedali Civili di Brescia | Azienda Ospedale San Giovanni | Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona | Azienda Ospedaliera Papa Giovanni XXIII | Azienda Ospedaliera Papa Giovanni XXIII, Bergamo | Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy | Azienda Ospedaliera Papa Giovanni XXIII (Former:Ospedali Riuniti di Bergamo) | Azienda Ospedaliera Spedali Civili, Brescia | Azienda Ospedaliera Spedali Civili di Brescia | Azienda Sanitaria Ospedale San Giovanni Battista Molinette di Torino | Brescia University | Centro Regionale Sclerosi Multipla Piazzale Spitali Civili 1 25123 Brescia | Chair of Haematology, Brescia University | Dipartimento di Medicina Interna, Nefrologia e dialisi - Ospedale San Giovanni Battista - Foligno (Perugia) Italy | Division of Hematology, A.O.U. San Giovanni Battista | Gono - ASST Spedali Civili Brescia | Gruppo Ospedaliero San Donato, Bergamo | Gruppo Ospedaliero San Donato, Policlinico San Pietro, Ponte San Pietro, Bergamo | Hematology Division. Ospedale San Giovanni Battista. Torino | IOSI, Ospedale San Giovanni | IOSI - Ospedale San Giovanni, Bellinzona | IOSI -Ospedale San Giovanni, Bellinzona | IOSI, Ospedale San Giovanni Bellinzona | Istituto Oncologico della Svizzera Italiana - Ospedale San Giovanni | Istituto Oncologico della Svizzera Italiana- Ospedale s.Giovanni - 6500 Bellinzona, Switzerland | Ospedale di Brescia | Ospedale San Giovanni | Ospedale San Giovanni di Roma | Ospedale SS Giovanni e Paolo - Venezia, Italy | Papa Giovanni XXIII Hospital | Papa Giovanni XXIII Hospital Bergamo | Radiotherapy Dept., Brescia Hospital and Brescia University | SCDO Ematologia 2 AOU San Giovanni Battista Torino | SCDO Ematologia AOU San Giovanni Battista Torino | S.C. Ematologia 2 ASO San Giovanni Battista Torino | S.C. Ematologia II - OSP.S. GIOV.BATTISTA MOLINETTE - TORINO (TO) - | Strutture Ospedaliere - Cliniche San Pietro - AOU Sassari | Università degli Studi di Brescia | Università degli Studi di Brescia ASST degli Spedali Civili di Brescia | University of Brescia (Italy) | University of Brescia, Italy | USC Ematologia, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy

Active Ingredients

Drugs in Phase 4 Trials (29)

aflibercept (zaltrap) (2 trials)

amino acids (Freamine) (1 trial)

amlodipine (norvasc) (1 trial)

beclomethasone (vanceril) (1 trial)

chickpea (1 trial)

cobicistat (stribild) (1 trial)

cyclophosphamide (cytoxan) (9 trials)

darunavir (prezista) (1 trial)

degarelix acetate (firmagon) (1 trial)

dinoprostone (prostin e2) (1 trial)

doxorubicin (Doxil) (5 trials)

ertapenem (invanz) (1 trial)

everolimus (zortress) (2 trials)

fludarabine (fludara) (2 trials)

fluticasone (cutivate) (1 trial)

formoterol (foradil) (1 trial)

indapamide (lozol) (1 trial)

indomethacin (indocin) (2 trials)

keto-amino acids (1 trial)

ketorolac (acuvail) (2 trials)

latanoprost (xalatan) (2 trials)

omega-3 fatty acids (Omacor) (2 trials)

perindopril (aceon) (1 trial)

pranoprofen (2 trials)

ranibizumab (lucentis) (2 trials)

rilpivirine (edurant) (1 trial)

rituximab (rituxan) (10 trials)

salmeterol (serevent) (1 trial)

tafluprost (zioptan) (1 trial)

Drugs in Phase 3 Trials (50)

allogeneic adipose derived mesenchymal stem cell (1 trial)

amiodarone (cordarone) (1 trial)

bicalutamide (casodex) (1 trial)

bifidobacterium breve (1 trial)

bifidobacterium infantis (1 trial)

bifidobacterium longum (1 trial)

bromfenac (xibrom) (1 trial)

busulfan (Myleran) (1 trial)

canrenone (Contaren) (1 trial)

capecitabine (xeloda) (1 trial)

carmustine (bicnu) (2 trials)

cetuximab (erbitux) (3 trials)

cisplatin (platinol) (5 trials)

cytarabine (cytosar-u) (2 trials)

dasatinib (sprycel) (1 trial)

docetaxel (taxotere) (3 trials)

dolutegravir (tivicay) (1 trial)

epirubicin (ellence) (2 trials)

epoetin (Epogen) (1 trial)

etoposide (vepesid) (3 trials)

fatty acid (2 trials)

Filgrastim (neupogen) (1 trial)

fluorouracil (efudex) (2 trials)

hydroxyurea (hydrea) (1 trial)

imatinib (gleevec) (2 trials)

infliximab (remicade) (1 trial)

Lactobacillus acidophilus (1 trial)

lactobacillus casei (1 trial)

lactobacillus delbrueckii (1 trial)

lactobacillus plantarum (1 trial)

lamivudine (epivir) (1 trial)

lenalidomide (revlimid) (2 trials)

melphalan (alkeran) (4 trials)

methylprednisolone (medrol) (1 trial)

mitotane (lysodren) (1 trial)

mitoxantrone (novantrone) (2 trials)

nepafenac (nevanac) (1 trial)

nilotinib (tasigna) (1 trial)

oxaliplatin (eloxatin) (1 trial)

peginterferon beta-1a (Plegridy) (1 trial)

prednisone (meticorten) (5 trials)

rolofylline (2 trials)

ropivacaine (naropin) (2 trials)

sargramostim (leukine) (3 trials)

streptococcus salivarius (1 trial)

thalidomide (Thalomid) (2 trials)

triptorelin (Trelstar) (1 trial)

urea (2 trials)

vincristine (oncovin) (3 trials)

vsl #3 (1 trial)

Drugs in Phase 2 Trials (48)

abiraterone (zytiga) (1 trial)

acalabrutinib (calquence) (1 trial)

aldesleukin (Proleukin) (1 trial)

allogeneic cik cells (1 trial)

allogeneic cord blood (1 trial)

atorvastatin (lipitor) (1 trial)

autologous hematopoietic stem cells (2 trials)

autologous mesenchymal stem cells (4 trials)

azacitidine (vidaza) (1 trial)

bevacizumab (avastin) (1 trial)

bortezomib (velcade) (2 trials)

cabazitaxel (jevtana kit) (1 trial)

carboplatin (paraplatin) (1 trial)

cord blood hematopoietic stem cell (1 trial)

cytokine induced killer cells (1 trial)

denosumab (prolia) (1 trial)

dorzolamide (trusopt) (1 trial)

echitabplus-icp (1 trial)

enzalutamide (xtandi) (1 trial)

epinephrine (levophed) (1 trial)

erlotinib (tarceva) (1 trial)

fludeoxyglucose f-18 (1 trial)

gefitinib (iressa) (1 trial)

gemcitabine (gemzar) (3 trials)

givinostat (2 trials)

ibritumomab tiuxetan (Zevalin) (3 trials)

irinotecan (Camptosar) (1 trial)

istaroxime (1 trial)

leucovorin (1 trial)

lisinopril (zestril) (1 trial)

melatonin (1 trial)

mirabegron (myrbetriq) (1 trial)

naltrexone (revia) (1 trial)

niraparib (zejula) (1 trial)

nms-03592088 (1 trial)

ofatumumab (arzerra) (1 trial)

paclitaxel (taxol) (2 trials)

pembrolizumab (keytruda) (1 trial)

pentostatin (nipent) (1 trial)

rostafuroxin (1 trial)

sonidegib (odomzo) (2 trials)

sorafenib (nexavar) (1 trial)

temozolomide (temodar) (2 trials)

temsirolimus (torisel) (1 trial)

tolvaptan (samsca) (1 trial)

triticum monococcum (1 trial)

umbilical cord mesenchymal stem cells (1 trial)

zoledronic acid (zometa) (3 trials)

Drugs in Phase 1 Trials (5)

blinatumomab expanded t-cells (1 trial)

obinutuzumab (gazyva) (1 trial)

sst 0001 (1 trial)

venetoclax (venclexta) (1 trial)

vinorelbine (navelbine) (1 trial)

Drugs in Other Trials (7)

carotenoid (1 trial)

COVID-19 convalescent plasma (2 trials)

lactobacillus reuteri (1 trial)

magnesium oxide (1 trial)

nevulose (1 trial)

oxycodone (oxycontin) (1 trial)

pregabalin (lyrica) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Disease (Phase 4)

Adrenocortical Carcinoma (Phase 3)

Appendicitis (Phase 4)

Asthma (Phase 4)

Atrial Fibrillation (Phase 3)

Brain Diseases (Phase 3)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Carcinoma, Squamous Cell (Phase 3)

Cardiomyopathies (Phase 3)

Cardiomyopathy, Dilated (Phase 3)

Celiac Disease (Phase 2)

Central Nervous System Neoplasms (Phase 2)

Colitis (Phase 3)

Colitis, Ulcerative (Phase 3)

Colorectal Neoplasms (Phase 2)

Crohn Disease (Phase 3)

Cushing Syndrome (Phase 2)

Diabetic Nephropathies (Phase 2)

Essential Hypertension (Phase 2)

Glaucoma (Phase 4)

Glaucoma, Open-Angle (Phase 4)

Glioblastoma (Phase 2)

Glomerulonephritis (Phase 3)

Glomerulonephritis, Membranous (Phase 3)

Graft vs Host Disease (Phase 2)

Head and Neck Neoplasms (Phase 3)

Heart Failure (Phase 3)

Hematologic Neoplasms (Phase 2)

Hepatic Encephalopathy (Phase 3)

Hydrophthalmos (Phase 2)

Hypertension (Phase 4)

Hypertrophy (Phase 2)

Hypertrophy, Left Ventricular (Phase 2)

Hyponatremia (Phase 2)

Infections (Phase 4)

Inflammation (Phase 3)

Inflammatory Bowel Diseases (Phase 3)

Intestinal Diseases (Phase 3)

Kidney Diseases (Phase 4)

Kidney Failure, Chronic (Phase 1)

Laryngeal Neoplasms (Phase 2)

Leukemia (Phase 3)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Leukemia, Myelomonocytic, Chronic (Phase 2)

Leukemia, Myelomonocytic, Juvenile (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 3)

Lymphoma, Follicular (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Lymphoma, Mantle-Cell (Phase 3)

Lymphoma, Non-Hodgkin (Phase 2)

Lymphoproliferative Disorders (Phase 4)

Macular Degeneration (Phase 4)

Macular Edema (Phase 4)

Mouth Neoplasms (Phase 2)

Multiple Myeloma (Phase 3)

Multiple Sclerosis (Phase 3)

Myelodysplastic Syndromes (Phase 2)

Myeloproliferative Disorders (Phase 2)

Nasopharyngeal Carcinoma (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Neoplasms, Plasma Cell (Phase 3)

Nervous System Neoplasms (Phase 2)

Ocular Hypertension (Phase 4)

Ovarian Cysts (Phase 3)

Ovarian Neoplasms (Phase 2)

Peritonitis (Phase 4)

Pharyngeal Neoplasms (Phase 2)

Polycythemia (Phase 3)

Polycythemia Vera (Phase 3)

Preleukemia (Phase 2)

Prostatic Neoplasms (Phase 4)

Sclerosis (Phase 3)

Shock (Phase 2)

Shock, Cardiogenic (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 3)

Stomach Neoplasms (Phase 3)

Syndrome (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Ulcer (Phase 3)

Uremia (Phase 4)

Urinary Bladder Neoplasms (Phase 2)

Vaginal Diseases (Phase 4)

Vaginosis, Bacterial (Phase 4)

Wet Macular Degeneration (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 103
  • # of Trial APIs: 139